Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

Biolytx Pharmaceuticals picks up $1.1 mill

    Home News Biolytx Pharmaceuticals picks up $1.1 mill
    NextPrevious

    Biolytx Pharmaceuticals picks up $1.1 mill

    By admin | News, SeedStep Angels | Comments are Closed | 11 November, 2015 | 0

    Biolytx Pharmaceuticals picks up $1.1 mill
    By Iris Dorbian
    © 2015 Buyouts Insider / Argosy Group LLC

    OKLAHOMA CITY, OK — A $500,000 investment from the i2E, Inc.-managed Oklahoma Seed Capital Fund recently led a $1.1 million financing round in Oklahoma City-based Biolytx Pharmaceuticals Corp.

    Biolytx is developing a promising drug designed to promote wound healing and kill antibiotic resistant bacteria.

    This latest financing round also included $200,000 from the i2E-managed SeedStep Angels group, as well as $250,000 from an Oklahoma venture capital fund and $150,000 in committed investment by Biolytx management.

    The company’s antimicrobial peptide program was developed by H. Anne Pereira, Ph.D.,
    Dean of the Graduate College & Professor and Associate Dean of Research for the College of Pharmacy at the University of Oklahoma Health Sciences Center, and licensed by OU to Biolytx.

    Biolytx plans to use the new investment dollars to further pre-clinical studies of its initial peptide for corneal wound healing, said William A. Hagstrom, co-founder and board member.

    Successful completion of those studies will enable Biolytx to move toward preparation and filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration.

    “We are excited to be taking this important step to move our peptide drug candidates from the discovery phase to clinical development, where we hope to address tremendous unmet needs in a range of wound healing and antibiotic resistance indications,” Hagstrom said.

    The SeedStep Angels group was founded by i2E in 2009 and is now the state’s largest angel investment group with more than 50 members and chapters in Oklahoma City, Tulsa, Ardmore and Muskogee.

    The Oklahoma Seed Capital Fund is a state-appropriated investment fund through the Oklahoma Center for the Advancement of Science and Technology.

    About Biolytx Pharmaceuticals
    Founded in 2005 by H. Anne Pereira, Ph.D., and William A. Hagstrom, Biolytx is a pharmaceutical technology company developing a novel antibiotic peptide for potential use in wound healing and treatment of serious hospital-acquired infections, including those resistant to current antibiotics. The technology was developed in the University of Oklahoma Health Sciences Center laboratory of Dr. Pereira and licensed from OU. Pereira’s research showed that a peptide from the CAP37 protein has the ability to kill antibiotic resistant bacteria in laboratory studies. For the past decade, Pereira and her Biolytx team have worked to synthesize the peptide in quantities large enough for use in clinical trials. http://www.biolytxcorp.com

    About i2E, Inc.
    With offices in Oklahoma City and Tulsa, OK, i2E’s nationally recognized services include business expertise and funding for Oklahoma’s emerging small businesses. i2E has more than $40 million of investment capital under management. www.i2E.org

    Biolytx Pharmaceuticals, i2E, OCAST, Seed Capital Fund, SeedStep Angels, University of Oklahoma Health Science Center

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Library
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592
    Click HERE for printable map with directions.
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • #withOklahomaStartups
    • #withOklahomaStartups
    • #withOklahomaStartups- copy
    • 2016 BrewFest
    • 2018 Paulsen Award Application
    • 2019 Business Plan Submittal Form
    • 2019 Intent to Compete
    • 2019 Oral Competition Submittal Form
    • 2019 Paulsen Award Application
    • 2020 Business Plan Submittal Form
    • 2020 Oral Competition Submittal Form
    • 2020 Paulsen Award Application
    • 2021 Official Application Form
    • 2021 Oral Competition Submittal Form
    • 2021 Paulsen Award Application
    • 4DSales
    • About
    • About i2E
    • About Us
    • ACT Tulsa
    • Add Listing
    • Alkami
    • Biolytx
    • BP Endo
    • Clear River Enviro
    • Concept Fund
    • Contact
    • COVID-19 News from i2E
    • COVID19 Resources for Scalable Startups
    • CreditPoint
    • Datebox
    • DermaMedics
    • DEX Pump
    • DigitalSix
    • Directory
    • Directory Dashboard
    • Docvia
    • Driven Analytics
    • e3
    • e3 Goes Virtual
    • e3: #withOklahomaStartups
    • Entrepreneurial Development
    • Entrepreneurial Summit
    • Entrepreneurial Summit Speakers
    • Entrepreneurs-in-Residence
    • Entrepreneurship
    • Events
    • Events
    • Exaptive
    • Exerbotics
    • Expert TA
    • Founder’s Book Nook
    • Home
    • Home
    • i2E Directory
    • i2E Events
    • iMCI
    • iMCI Investment Funds
    • Investments
    • iRecommend
    • Kirrhos
    • Letter from iMCI’s Executive in Residence in a time of great uncertainty
    • Library
    • Lifetone
    • Linear Health Sciences
    • Love’s Cup
      • Forms
      • High Growth
      • Paulsen Awards
      • Small Business
      • Timeline
    • Love’s Cup is Unstoppable
    • Love’s Cup W-9
    • MaxQ
    • Moleculera Labs
    • Monscierge
    • MS Pen Technologies
    • My Account
    • News
    • Newsletter
    • Newsletter Archive
    • OKBio
    • OKBio Directory
    • OMRF Glioblastoma
    • Otologics Pharmaceuticals
    • Past Winners
    • PhotoniCare
    • PolySkope Labs
    • Portfolio
    • Portfolio 3
    • Private Partners Opportunity Fund
    • Progentec Diagnostics
    • Q&A with Kevin Moore
    • Q&A with Michael Basch
    • Quarterly Report
    • Raw Space for Rent
    • Resources
    • Roll to Roll Technologies
    • Selexys Pharmaceuticals
    • Send a Ride
    • Simergent
    • Spiers New Technologies
    • Synercon Technologies
    • Tailwind
    • Ten Nine Technologies
    • Testimonials
    • Tetherex Pharmaceuticals
    • The Greg Main Distinguished Scholar Award
    • THG Energy Solutions
    • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
    • Thoughts Post Shut In
    • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
    • Tulsa GEW
    • Valve Systems International
    • Venture Advisory Services
    • Video
    • Virtuoso
    • Webmail Test Page
    • WeGoLook
    • Well Checked Systems
    • Whiteboard CRM
    i2E